HUTCHMED Welcomes New Board Member with Oncology Expertise

HUTCHMED Strengthens Leadership with New Appointment

Today marks an exciting chapter for HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) as it officially appoints Professor Tan Shao Weng as an Independent Non-executive Director and member of its Technical Committee. This impressive addition brings considerable expertise to the team, effective from October 15.

Meet Professor Tan Shao Weng

With over two decades of experience in oncology, Professor Tan's work primarily revolves around thoracic and head and neck malignancies. He holds notable positions at the National Cancer Centre Singapore as the head of Clinical Trials and Epidemiological Sciences, as well as a senior consultant in Medical Oncology. Additionally, he is a respected professor at Duke-NUS Medical School.

Endorsement from Leadership

Dr. Dan Eldar, Chairman of HUTCHMED, expressed his enthusiasm regarding Professor Tan's appointment. He emphasized that Professor Tan's extensive background in early phase clinical trials and innovative therapies is expected to significantly benefit the company. Dr. Eldar noted how his expertise aligns perfectly with HUTCHMED's focus on cancer drug development.

Professor Tan's Contributions to Oncology

Leading the Experimental Cancer Therapeutics Unit at NCCS, which is one of the largest Phase I clinical trial units in Asia, Professor Tan spearheads numerous trials, showcasing his dedication to advancing cancer treatment. Furthermore, he leads critical research aimed at both understanding drug resistance and developing new cancer therapies and biomarkers.

Acknowledgments and Publications

Professor Tan has received various accolades for his contributions to the field, including prestigious awards from the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology. He has authored over 200 peer-reviewed articles in renowned medical journals, establishing himself as a leader in his field.

Educational Background

His academic achievements include a Bachelor of Science with first-class honors in tumor biology from University College London, along with a Bachelor of Medicine and Surgery from St Bartholomew's. Additionally, he earned a PhD from the National University of Singapore, and he is a Fellow of the Royal College of Physicians.

Company Growth and Future Directions

As HUTCHMED continues to expand its reach in the biopharmaceutical industry, the appointment of Professor Tan comes at a pivotal moment. The company remains committed to developing targeted therapies and immunotherapies, aimed at improving outcomes for cancer patients globally. HUTCHMED's first three medicines have been successfully marketed in China, with international approvals, illustrating its growth trajectory.

Looking Ahead

With Professor Tan's unparalleled background in oncology, HUTCHMED is poised not only to innovate further in the realm of cancer treatment but also to enhance its global presence as a leader in biopharmaceutical solutions. His insights and leadership will help drive the company toward fulfilling its mission of delivering impactful therapies to patients worldwide.

Transparency and Governance

In line with governance standards, Professor Tan has confirmed his independence from any conflicts that may affect his role. The appointment will undergo review as per the company's Articles of Association and regulatory guidelines, ensuring HUTCHMED adheres to high standards of corporate governance.

CONTACTS

For Investor inquiries, please contact HUTCHMED at +852 2121 8200 or via email at ir@hutch-med.com. For Media inquiries, FTI Consulting can be reached at +44 20 3727 1030.

Frequently Asked Questions

Who has been appointed as a new board member of HUTCHMED?

Professor Tan Shao Weng has been appointed as an Independent Non-executive Director.

What is Professor Tan's area of expertise?

He specializes in oncology, particularly thoracic and head/neck malignancies.

What recognition has Professor Tan received?

He has received several prestigious awards, including from the IASLC and ASCO.

What are HUTCHMED's primary focuses?

The company focuses on the discovery and commercialization of targeted therapies and immunotherapies for cancer.

How can I find more information about HUTCHMED?

More information can be found on their official website or through their investor contacts.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.